leadf
logo-loader
view4D pharma PLC

4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company.

Peyton says the merger will accelerate and de-risk 4D's admission to NASDAQ while providing immediate access to additional funds to support the group's pipeline of therapies. He adds it also will likely increase interest from US healthcare investors provide access to a much larger pool of specialist capital.

Quick facts: 4D pharma PLC

Price: 99.8 GBX

LSE:DDDD
Market: LSE
Market Cap: £131.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

4D Pharma PLC about to start dosing patients in its Phase II trial for COVID-19

4D pharma plc's (LON:DDDD) Duncan Peyton tells Proactive London's Andrew Scott they're focused on live biotherapeutics - a new class of therapeutics which uses bacteria as drugs. ''Even though it's a new area we've made a lot of progress in the five years we've been going ... we've got our...

on 05/29/2020

2 min read